Debiotech S.A.

Debiotech S. A. is a Swiss company focused on developing innovative medical devices that enhance patient safety and health outcomes through advanced drug delivery systems and specialized healthcare solutions. Founded in 1990 and headquartered in Lausanne, Switzerland, Debiotech S.

A. specializes in medical technology. The company was involved in a significant deal in October 2004 when Animas LLC acquired its insulin micro-pump technology for USD 12 mn. CEO Laurent-Dominique Piveteau leads the firm, which has conducted one notable deal to date.

Debiotech specializes in the development of innovative medical devices that enhance patient safety and improve health outcomes. Its core product offerings include advanced drug delivery systems such as large volume injectors, insulin on-body injectors, and peritoneal dialysis systems, designed to simplify the administration of medications and treatments. The company also develops specialized devices like intravenous injectors, hemodialysis systems, intradermal micro-needles, and flow control systems for injectors. These products aim to address specific healthcare challenges, such as the need for precise medication delivery and improved patient compliance, with clients ranging from healthcare providers to patients requiring chronic disease management solutions across Europe, North America, and parts of Asia.

Debiotech generates revenue through a combination of direct sales and partnerships within the medical device industry. It engages in B2B transactions with hospitals, clinics, and healthcare organizations procuring its devices for patient care. Revenue is also supported by collaborations with pharmaceutical companies seeking to integrate Debiotech’s drug delivery systems into their offerings. Pricing for products varies based on complexity, with flagship items like insulin on-body injectors commanding premium prices due to advanced features, reflecting the commitment to delivering high-quality medical devices that enhance patient treatment experiences.

Debiotech plans to utilize the funds from its most recent deal, where Animas LLC acquired insulin micro-pump technology for USD 12 mn, to support the development of new products and expansion efforts. The company is focusing on launching new devices aimed at enhancing drug delivery efficiency and patient compliance in 2025. Additionally, it aims to expand its presence in emerging markets in Asia and South America by 2026, thereby increasing its global footprint and addressing the growing demand for advanced medical solutions.